PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Julia:ReplicateBE – release 0.2.0

Опубликовано 26 октября, 201926 октября, 2019 frozencat

doiGitHub

Вот и подоспел релиз 0.2.0 для оценки параметров смешанной модели репликативного дизайна биоэквивалентности по методу С (EMA) – FDA model.

 

Рубрики: IT, Julia, Mixed Model, Биоэквивалентность

Навигация по записям

Предыдущая запись: ClinicalTrialUtilities: обзор
Следующая запись: Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180131 135955
20180816 213225
20180815 172001
IMG-20170807-WA0039
IMG-20170806-WA0046
20180815 150824
  • Generic Drug User Fee Amendments
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-30 By FDA
  • October - December 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • eCTD Submission Standards for eCTD v3.2.2 and Regional M1
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • eCTD Submission Standards for eCTD v4.0 and Regional M1
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • Internet Pharmacy Warning Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 36, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Date of authorisation: 20/06/2019, Revision: 11, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Green Lumber Holding, LLC Issues Consumer Alert on Counterfeit Products Following FDA Findings
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • Human medicines European public assessment report (EPAR): Nubeqa, darolutamide, Date of authorisation: 27/03/2020, Revision: 10, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Jeraygo, aprocitentan, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
Предыдущие записи
Тема: Scaffold от Danny Cooper.